Navigation Links
Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
Date:4/24/2013

 

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a first-in-class biologic in Phase 2 clinical development as a potential new treatment for allergic asthma.

CYT003 acts via a novel, allergen-independent mechanism of action to selectively suppress the body's immune response to allergens, a predominant risk factor for asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function and asthma control in patients with persistent allergic asthma, even as standard inhaled corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in over 450 patients to date.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

http://www.cytos.com 

This foregoing press release may contain forward-looking statements that include words or phrases such as "are intended for", "are designed to", or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory autho
'/>"/>

SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
2. Cytos Biotechnology Strengthens Management Team
3. Plandai Biotechnology, Inc. Announces Shipment Of First Machinery To South African Production Facility
4. PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs
5. Choose New Jersey and Partners to Promote New Jersey As Global Life Science Hub at Worlds Largest Biotechnology Event
6. Plandai Biotechnology, Inc. Enters Into License Agreement With Phyto Nutricare To Develop Nutraceutical Products
7. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
8. NanoSight, One of the UKs Fastest Growing Biotechnology Companies, Wins a 2013 Queens Award for Enterprise - Innovation
9. Global Biotechnology Industry Market Research Report Now Available from IBISWorld
10. Plandai Biotechnology, Inc. Updates Progress Of Preparing Products For Market
11. San Diego State University Hosts Open House for Life Science Immersion Biotechnology Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... rainbow arches from its HQ all the way to prison. ... its old image of ENWRONG to PRISMA. After paying $665 million ... of PRISMA while some of its executives walk to prison. The ... staff of 5000 in 25 different business units, a big drop ...
... I had to reboot my washing machine. Not just turning ... I pulled the power plug from the wall, waited a ... into the outlet. Flashing lights, a trill of beeps, and ... got me to thinking just how complicated ordinary machines have ...
... Wis. -- Small Tree Communications , a Midwestern ... focus on Mac OS X, has announced a free ... ,Link aggregation, an implementation of the IEEE 802.3ad ... into one virtual interface, combining the individual ports' bandwidth ...
Cached Biology Technology:Why is Enron now called Prisma? 2Why is Enron now called Prisma? 3Have you rebooted? 2Have you rebooted? 3Have you rebooted? 4
(Date:4/17/2014)... Pine forests are chock full of wild animals and ... populations of fungi are churning away in the soil, ... , Despite the vital role these fungi play in ... A Stanford-led team of scientists has generated a genetic ... North America. The work was published this week in ...
(Date:4/17/2014)... of our ideas about domestication derive from Charles ... by British animal-breeding practices during the 19th century, ... improvement. , It is from Darwin that ... of captive animals from wild species and total ... But animal management in this industrial setting has ...
(Date:4/16/2014)... ,, From far away, the top of a leaf ... smooth exterior is actually made up of a patchwork ... Interested in how these cells individually take on their ... Arun Sampathkumar, and colleagues sought to pinpoint the shape-controlling ...
Breaking Biology News(10 mins):Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4For cells, internal stress leads to unique shapes 2
... February 4, 2011 Ben-Gurion University of the Negev ... Katz Institute for Nanoscale Science and Technology, has been ... Research. Dr. Mokari received the Prize for his ... ,Dr. Mokari is a senior lecturer in ...
... DURHAM, N.C. Timing is everything in the long-standing arms ... Hyaloperonospora , a downy mildew pathogen. Duke University researchers ... immune system in the morning to prepare for the greatest ... isn,t news that plants know what time of day it ...
... N.Y. Growing up poor increases a person,s likelihood ... study led by a Cornell University environmental psychologist shows ... offset this disadvantage of poverty. The study, "Loosening ... Obesity : The Protective Effects of Social Capital" published ...
Cached Biology News:Plant's immune defense revs up for the morning attack 2Plant's immune defense revs up for the morning attack 3Cornell researchers find a strong community protects adolescents from risky health behavior 2
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
Biology Products: